Novartis AG
NVSEF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001114448
No open-market purchases or sales by Novartis AG insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $6.28M in total; no superinvestor holds it.
Other share classesNVS
Q4 2025 vs. Q3 2025
How the institutions holding Novartis AG changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 4 | 2 | −2 |
| Shares | 190.1K | 49.4K | −140.7K (−74.0%) |
| Value | $23.9M | $6.82M | −$17.1M (−71.5%) |
New holders (0)
Institutions that held Novartis AG at the end of Q4 2025 but not at the end of Q3 2025.
None.
Sold out (2)
Institutions that held Novartis AG at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Boston Common Asset Management, LLC | 129,013 | $16.2M |
| Saranac Partners Ltd | 560 | $70.5K |